This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem Congratulates Lee Clough On Winning Award From American Society For Apheresis

Stocks in this article: NBS

NEW YORK, March 31, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Lee Clough, RN, HP (ASCP), Director of Clinical Affairs & Apheresis for Progenitor Cell Therapy (PCT), a wholly-owned subsidiary of NeoStem, has been awarded the SHS Award from the American Society for Apheresis (ASFA). Ms. Clough will be presented with the award at the ASFA Annual Business Meeting Luncheon in San Francisco, CA on April 4, 2014.

The SHS award is given to an allied health member who has demonstrated sincere commitment to apheresis (a medical technology in which the blood of a patient is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation), and who has emerged as a leader and role model in the field. The SHS Award (short for The Society for Hemapheresis Specialists) was the first national organization in the United States which provided a forum for the professional development of technical specialists in the field of apheresis. This award commemorates the pioneering efforts of SHS which have culminated in the high standards and sophistication which characterize the field of American apheresis.

"I am excited and proud to be honored with this award by my peers for a job I love to do," said Ms. Clough. "I am committed to educating people about apheresis and training technicians to do it well. The job comes with a certain satisfaction in knowing that you are training people who will be out in the field saving lives."

Ms. Clough joined PCT in 2009 and is an integral part of PCT's cellular therapy business, as well as NeoStem's adult stem cell and cord blood collection, processing and storage business (NeoStem Family Storage). She regularly oversees the apheresis portion of PCT's clients' specific cellular therapy projects, writes and updates the company's apheresis procedures, trains staff in apheresis collection, and assists PCT's clients in assessing and training their collection sites for their clinical trial programs. She began her apheresis career at Children's Hospital of Philadelphia and, prior to her time with PCT, she worked at Inova, managing five donor centers and a therapeutic apheresis center, and at Dendreon as an apheresis specialist. She earned her B.S.N. at the University of Delaware.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs